E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER |
CARCINOMA POLMONARE NON A PICCOLE CELLULE PD-L1–POSITIVO LOCALMENTE AVANZATO O METASTATICO |
|
E.1.1.1 | Medical condition in easily understood language |
Treatement of advanced lung cancer which has spread to other part of the body. |
Trattamento di Carcinoma Polmonare avanzato che si è esteso ad altre parti del corpo. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061873 |
E.1.2 | Term | Non-small cell lung cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective for this study is to evaluate the efficacy of MPDL3280A in patients with programmed cell death−1 ligand 1 (PD-L1)−positive locally advanced or metastatic non−small cell lung cancer (NSCLC), as measured by:
• Independent review facility (IRF)-assessed objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Investigator-assessed ORR according to modified RECIST. |
Obiettivo primario di questo studio è quello di valutare l’efficacia di MPDL3280A in pazienti con carcinoma polmonare non a piccole cellule (non-small cell lung cancer, NSCLC) positivo per il programmed cell death-1 ligand 1 (PD-L1), localmente avanzato o metastatico, misurata come:
•Tasso di risposte obiettive (objective response rate, ORR) valutato dal Comitato di Revisione Indipendente (Independent review facility, IRF) secondo i Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
•ORR valutato dallo sperimentatore secondo i criteri RECIST modificati.
|
|
E.2.2 | Secondary objectives of the trial |
• To evaluate progression-free survival (PFS) and duration of response (DOR) according to RECIST v1.1 as assessed by IRF and according to modified RECIST as assessed by the investigators
• To evaluate ORR, DOR, and PFS according to RECIST v1.1 as assessed by the investigators
• To evaluate overall survival (OS) |
Gli obiettivi secondari del presente studio sono:
•Valutare la sopravvivenza libera da progressione (progression-free survival, PFS) e la durata della risposta (duration of response, DOR) secondo i criteri RECIST v1.1 in base alle valutazioni dell’IRF e secondo i criteri RECIST modificati in base alle valutazioni degli sperimentatori
•Valutare l’ORR, la DOR e la PFS secondo i criteri RECIST v1.1 in base alle valutazioni degli sperimentatori
•Valutare la sopravvivenza globale (overall survival, OS)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Histologically or cytologically documented Stage IIIB (not eligible for definitive chemoradiotherapy), Stage IV, or recurrent NSCLC
• PD-L1-positive status as determined by an IHC assay performed by a central laboratory
• ECOG performance status of 0 or 1
• Life expectancy > 12 weeks
• Measurable disease, as defined by RECIST v1.1
|
- Carcinoma polmonare non a piccole cellule (NSCLC) di stadio IIIB documentato con esame istologico o citologico (non elegibile per radioterapia definitiva), di stadio IV, o ricorrente.
- Stato PD-L1 positivo come documentato da test immunoistochimico svolto da un laboratorio centrale
- Performance status ECOG di 0 o 1
- Aspettativa di vita > 12 settimane
- Malattia misurabile secondo i criteri RECIST v1.1 |
|
E.4 | Principal exclusion criteria |
• Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
• Known CNS disease, including treated brain metastases
• Leptomeningeal disease
• History of auto-immune disease |
- Trattamento con qualunque altro farmaco sperimentale o partecipazione ad un’altra sperimentazione clinica nei 28 giorni precedenti l’arruolamento
- Patologie note del sistema nervoso centrale, comprese metastasi cerebrali trattate
- Patologie della leptomeninge
- Anamnesi di malattie autoimmuni |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The co-primary endpoints of this study will be IRF-assessed ORR according to RECIST v1.1 and investigator-assessed ORR according to modified RECIST criteria . |
Gli endpoint coprimari di questo studio saranno rappresentati dall’ORR valutato dall’IRF secondo i criteri RECIST v1.1 e dall’ORR valutato dallo sperimentatore secondo i criteri RECIST modificati. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Please refer to section E.5.1 |
|
E.5.2 | Secondary end point(s) |
• PFS assessed by IRF per RECIST v1.1
• PFS assessed by investigator per modified RECIST
• OS |
- PFS valutata dall’IRF secondo i criteri RECIST v1.1
- PFS valutata dallo sperimentatore secondo i criteri RECIST modificati
- Sopravvivenza globale (OS)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Please refer to section E.5.2 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Belgium |
Bulgaria |
Canada |
France |
Italy |
Netherlands |
Germany |
Spain |
Slovenia |
Switzerland |
Turkey |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is defined as the date of the last follow-up visit of the last patient enrolled and is expected to occur approximately 12 months after the last patient enrolls in the study. |
La fine dello studio è definita come la data dell’ultima visita di follow-up dell’ultimo paziente arruolato e ci si aspetta che cadrà circa 12 mesi dopo l’arruolamento dell’ultimo paziente nello studio. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |